IOL Chemicals and Pharmaceuticals Temettüler ve Geri Alımlar
Temettü kriter kontrolleri 3/6
IOL Chemicals and Pharmaceuticals kazançlarla iyi bir şekilde karşılanan, 1.35% cari getiriye sahip, temettü ödeyen bir şirkettir.
Anahtar bilgiler
1.3%
Temettü verimi
n/a
Geri Alım Getirisi
Toplam Hissedar Getirisi | n/a |
Gelecekteki Temettü Verimi | 1.0% |
Temettü Büyümesi | 7.9% |
Bir sonraki temettü ödeme tarihi | n/a |
Eski temettü tarihi | n/a |
Hisse başına temettü | ₹5.000 |
Ödeme oranı | 22% |
Son temettü ve geri alım güncellemeleri
Recent updates
A Piece Of The Puzzle Missing From IOL Chemicals and Pharmaceuticals Limited's (NSE:IOLCP) Share Price
Sep 11Is There An Opportunity With IOL Chemicals and Pharmaceuticals Limited's (NSE:IOLCP) 34% Undervaluation?
Jun 12Is IOL Chemicals and Pharmaceuticals (NSE:IOLCP) Using Too Much Debt?
Aug 30IOL Chemicals and Pharmaceuticals (NSE:IOLCP) Has A Pretty Healthy Balance Sheet
May 18IOL Chemicals and Pharmaceuticals (NSE:IOLCP) Will Pay A Dividend Of ₹4.00
Feb 10Is IOL Chemicals and Pharmaceuticals (NSE:IOLCP) Using Too Much Debt?
Jun 07Calculating The Intrinsic Value Of IOL Chemicals and Pharmaceuticals Limited (NSE:IOLCP)
May 07Do IOL Chemicals and Pharmaceuticals's (NSE:IOLCP) Earnings Warrant Your Attention?
May 04Is IOL Chemicals and Pharmaceuticals Limited (NSE:IOLCP) An Attractive Dividend Stock?
Mar 13Is IOL Chemicals and Pharmaceuticals (NSE:IOLCP) Using Too Much Debt?
Feb 23Should You Rely On IOL Chemicals and Pharmaceuticals' (NSE:IOLCP) Earnings Growth?
Feb 08IOL Chemicals and Pharmaceuticals Limited's (NSE:IOLCP) Recent Stock Performance Looks Decent- Can Strong Fundamentals Be the Reason?
Jan 27How Does IOL Chemicals and Pharmaceuticals' (NSE:IOLCP) CEO Salary Compare to Peers?
Jan 15Estimating The Intrinsic Value Of IOL Chemicals and Pharmaceuticals Limited (NSE:IOLCP)
Jan 02Shareholders of IOL Chemicals and Pharmaceuticals (NSE:IOLCP) Must Be Delighted With Their 869% Total Return
Dec 21Is Now The Time To Put IOL Chemicals and Pharmaceuticals (NSE:IOLCP) On Your Watchlist?
Dec 09These 4 Measures Indicate That IOL Chemicals and Pharmaceuticals (NSE:IOLCP) Is Using Debt Reasonably Well
Nov 24IOL Chemicals and Pharmaceuticals (NSE:IOLCP) Could Be A Buy For Its Upcoming Dividend
Nov 12Is There More To The Story Than IOL Chemicals and Pharmaceuticals's (NSE:IOLCP) Earnings Growth?
Nov 09Will Weakness in IOL Chemicals and Pharmaceuticals Limited's (NSE:IOLCP) Stock Prove Temporary Given Strong Fundamentals?
Oct 27Here's What We Think About IOL Chemicals and Pharmaceuticals' (NSE:IOLCP) CEO Pay
Oct 09Calculating The Fair Value Of IOL Chemicals and Pharmaceuticals Limited (NSE:IOLCP)
Sep 18Here's Why I Think IOL Chemicals and Pharmaceuticals (NSE:IOLCP) Might Deserve Your Attention Today
Sep 03Cautious Investors Not Rewarding IOL Chemicals and Pharmaceuticals Limited's (NSE:IOLCP) Performance Completely
Aug 16IOL Chemicals and Pharmaceuticals (NSE:IOLCP) Seems To Use Debt Rather Sparingly
Jul 27Ödemelerde İstikrar ve Büyüme
Temettü verilerini getirme
İstikrarlı Temettü: IOLCP 10 yıldan az bir süredir temettü ödüyor ve bu süre zarfında ödemeler dalgalı oldu.
Büyüyen Temettü: IOLCP şirketinin temettü ödemeleri artmış, ancak şirket yalnızca 5 yıldır temettü ödemiştir.
Piyasaya Karşı Temettü Getirisi
IOL Chemicals and Pharmaceuticals Piyasaya Karşı Temettü Getirisi |
---|
Segment | Temettü Verimi |
---|---|
Şirket (IOLCP) | 1.3% |
Pazarın Alt %25'i (IN) | 0.2% |
Pazarın En İyi %25'i (IN) | 1.2% |
Sektör Ortalaması (Pharmaceuticals) | 0.7% |
Analist tahmini (IOLCP) (3 yıla kadar) | 1.0% |
Önemli Temettü: IOLCP 'in temettüsü ( 1.35% ), Indian piyasasındaki temettü ödeyenlerin en alttaki %25'inden ( 0.25% ) daha yüksektir.
Yüksek Temettü: IOLCP 'in temettüsü ( 1.35% ) Indian pazarındaki temettü ödeyenlerin en üst %25'indedir ( 1.15% )
Hissedarlara Ödenen Kazanç
Kazanç Kapsamı: Düşük ödeme oranı ( 21.8% ) ile IOLCP 'un temettü ödemeleri kazançlarla iyi bir şekilde karşılanıyor.
Hissedarlara Nakit Ödeme
Nakit Akışı Kapsamı: IOLCP temettü ödüyor ancak şirketin serbest nakit akışı yok.